ALMS1 (Q8TCU4) variants and mutations
ALMS1 (also known as Q8TCU4) is a human protein-coding gene encoding a centrosome-associated protein. It contributes to primary-cilium function, intracellular trafficking, and metabolic homeostasis in multiple tissues. Biallelic pathogenic variants cause Alstrom syndrome, which typically combines retinal degeneration, hearing loss, obesity, insulin resistance, and cardiomyopathy. This analysis covers 6,651 ALMS1 variants and mutations. Of these, 75% have computational variant effect predictions. Disease context includes Alstrom syndrome, Bardet-Biedl syndrome, and Abnormality of the cardiovascular system. Example ALMS1 variants include M1?, M1I, and M1L.
Variant analysis overview
- Gene: ALMS1
- Protein: Q8TCU4
- UniProt accession: Q8TCU4
- Organism: Homo sapiens
- Variants analyzed: 6651
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 6,339 unspecified-consequence records; 49 frameshift variants; 125 missense variants; 84 synonymous variants; 26 in-frame deletions; 11 stop-gained variants; 17 in-frame insertions; 2 substitution
- Prediction scores: 5,017 variants have prediction scores (75% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Alstrom syndrome, Bardet-Biedl syndrome, Abnormality of the cardiovascular system, Retinal dystrophy, Leber congenital amaurosis, retinitis pigmentosa, cardiomyopathy, Intellectual disability, intelligence, eye disorder, Hearing impairment, Cone rod dystrophy.
Protein structure and variant hotspots
- Protein features: 6 post-translational modification sites.
- PTM context: 4 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable ALMS1 variants
Examples include M1?, M1I, M1L, M1R, M1V, E2*, E2D, E2Q. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- M1I (p.Met1Ile), rs2104056063, ClinGen CA347250325, ClinVar RCV001375251, MetaLR 0.12, MetaSVM -0.95, Likely pathogenic, Hearing impairment
- M1L (p.Met1Leu), rs1429891881, ClinGen CA347250315, ClinVar RCV002612294, MetaLR 0.12, MetaSVM -0.98, Likely pathogenic, Alstrom syndrome
- M1R (p.Met1Arg), rs1553396091, ClinGen CA347250323, ClinVar RCV000666768, MetaLR 0.12, MetaSVM -0.97, Alstrom syndrome
- M1V (p.Met1Val), rs1429891881, ClinGen CA347250317, ClinVar RCV002050832, MetaLR 0.12, MetaSVM -0.98, Conflicting interpretations, Alstrom syndrome
- E2* (p.Glu2Ter), rs1670504473, ClinGen CA347250331, ClinVar RCV002867716, CADD 37.00, Pathogenic
- E2D (p.Glu2Asp), ExAC rs781075077, TOPMed rs781075077, gnomAD rs781075077, MetaLR 0.04, MetaSVM -1.05
- E2Q (p.Glu2Gln), TOPMed rs1670504473, MetaLR 0.07, MetaSVM -1.11
- E2A (p.Glu2Ala), gnomAD 2-73385872-G-GC, CADD 29.30
- P3L (p.Pro3Leu), rs914898490, ClinGen CA50368580, ClinVar RCV001293515, ClinVar RCV001359484, MetaLR 0.05, MetaSVM -1.04, Uncertain significance, Cardiovascular phenotype; not specified; Alstrom syndrome
- P3S (p.Pro3Ser), rs1053425100, ClinGen CA50368574, ClinVar RCV003083875, TOPMed rs1053425100, MetaLR 0.12, MetaSVM -1.05, Uncertain significance, Alstrom syndrome
- P3I (p.Pro3Ile), gnomAD 2-73385874-G-GAT, CADD 28.80
- P3T (p.Pro3Thr), gnomAD 2-73385875-C-A, MetaLR 0.11, MetaSVM -1.05
- P3P (p.Pro3Pro), gnomAD 2-73385877-C-G, CADD 3.74
- E4* (p.Glu4Ter), rs1553396092, ClinGen CA347250350, ClinVar RCV000670265, Ensembl rs1553396092, CADD 36.00, Likely pathogenic
- E4D (p.Glu4Asp), rs1260367236, ClinGen CA347250359, ClinVar RCV001889862, TOPMed rs1260367236, MetaLR 0.07, MetaSVM -1.09, Uncertain significance, Alstrom syndrome
- E4G (p.Glu4Gly), gnomAD rs1232846337, MetaLR 0.08, MetaSVM -1.11
- E4R (p.Glu4Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E4Q (p.Glu4Gln), gnomAD 2-73385878-G-C, MetaLR 0.09, MetaSVM -1.10
- D5E (p.Asp5Glu), Ensembl rs1574423572
- D5Y (p.Asp5Tyr), TOPMed rs1670504928
- p.Asp5 Glu20del, gnomAD 2-73385877-CGAGGA, CADD 20.90
- D5A (p.Asp5Ala), gnomAD 2-73385881-GAT-G, CADD 26.10
- L6M (p.Leu6Met), gnomAD 2-73385884-C-A, MetaLR 0.08, MetaSVM -1.08
- L6L (p.Leu6Leu), gnomAD 2-73385886-G-A, CADD 3.21
- P7L (p.Pro7Leu), TOPMed rs1670505146
- P7S (p.Pro7Ser), TOPMed rs1219519621, gnomAD rs1219519621, MetaLR 0.12, MetaSVM -1.04
- P7H (p.Pro7His), gnomAD 2-73385885-TG-T, CADD 11.30
- P7T (p.Pro7Thr), gnomAD 2-73385887-C-A, MetaLR 0.12, MetaSVM -1.04
- P7P (p.Pro7Pro), rs373614102, gnomAD 2-73385889-A-T, CADD 4.86
- W8R (p.Trp8Arg), gnomAD rs1348138067, MetaLR 0.07, MetaSVM -1.12, Uncertain significance, Alstrom syndrome
- W8G (p.Trp8Gly), gnomAD 2-73385890-T-G, MetaLR 0.06, MetaSVM -1.13
- W8C (p.Trp8Cys), gnomAD 2-73385891-G-GTTG, CADD 27.20
- W8* (p.Trp8Ter), gnomAD 2-73385892-G-A, CADD 36.00
- P9L (p.Pro9Leu), rs1297606865, ClinGen CA347250417, cosmic curated COSV52508, ClinVar RCV004521784, MetaLR 0.12, MetaSVM -0.82, Uncertain significance, Cardiovascular phenotype; not provided
- P9Q (p.Pro9Gln), gnomAD rs1297606865, MetaLR 0.12, MetaSVM -1.05, Uncertain significance
- P9S (p.Pro9Ser), rs769538172, ClinGen CA1712721, ClinVar RCV000794450, ClinVar RCV002424808, MetaLR 0.12, MetaSVM -1.05, Uncertain significance
- P9T (p.Pro9Thr), gnomAD 2-73385893-C-A, MetaLR 0.12, MetaSVM -1.05
- P9P (p.Pro9Pro), rs1283224132, gnomAD 2-73385895-G-A, CADD 7.33
- G10D (p.Gly10Asp), Ensembl rs1670505917, MetaLR 0.02, MetaSVM -0.99
- G10S (p.Gly10Ser), rs1045405319, ClinGen CA50368628, ClinVar RCV000665049, TOPMed rs1045405319, MetaLR 0.02, MetaSVM -1.02, Uncertain significance
- G10C (p.Gly10Cys), gnomAD 2-73385896-G-T, MetaLR 0.06, MetaSVM -1.06
- G10R (p.Gly10Arg), gnomAD 2-73385896-G-C, MetaLR 0.05, MetaSVM -1.06
- G10G (p.Gly10Gly), rs1402244580, gnomAD 2-73385898-C-T, CADD 13.40
- E11* (p.Glu11Ter), rs2465969801, ClinGen CA347250432, ClinVar RCV003171643, ClinVar RCV003609261, Pathogenic
- E11R (p.Glu11Arg), gnomAD 2-73385894-C-CT, CADD 25.20
- E11G (p.Glu11Gly), gnomAD 2-73385899-GA-G, CADD 28.70
- E11V (p.Glu11Val), gnomAD 2-73385900-A-T, MetaLR 0.08, MetaSVM -1.11
- E11D (p.Glu11Asp), gnomAD 2-73385901-G-T, MetaLR 0.08, MetaSVM -1.10
- E11E (p.Glu11Glu), rs1217067369, gnomAD 2-73385901-G-A, CADD 14.40
- L12Q (p.Leu12Gln), cosmic curated COSV52518, Ensembl rs200709146, MetaLR 0.10, MetaSVM -1.09
- L12V (p.Leu12Val), cosmic curated COSV10458, gnomAD rs199611703
- p.Leu12 Glu28del, gnomAD 2-73385898-CGAGCT, CADD 21.00
- L12L (p.Leu12Leu), rs199611703, gnomAD 2-73385902-C-T, CADD 15.10
- L12R (p.Leu12Arg), rs1670506403, gnomAD 2-73385902-CT-C, CADD 28.80
- p.Leu12 Glu13insVal, rs1244345693, gnomAD 2-73385902-C-CTGG, CADD 21.70
- E13G (p.Glu13Gly), rs1574423651, ClinGen CA347250456, ClinVar RCV001963912, Ensembl rs1574423651, AlphaMissense 0.54, MetaLR 0.07, Uncertain significance, Alstrom syndrome
- E13V (p.Glu13Val), Ensembl rs1574423651, AlphaMissense 0.54, MetaLR 0.07, Uncertain significance
- E13R (p.Glu13Arg), gnomAD 2-73385903-TGGAGG, CADD 29.50
- E13* (p.Glu13Ter), gnomAD 2-73385905-G-T, CADD 36.00
- E13D (p.Glu13Asp), gnomAD 2-73385907-G-T, MetaLR 0.06, MetaSVM -1.10
- E14K (p.Glu14Lys), rs2465969974, ClinGen CA347250462, ClinVar RCV002333735, MetaLR 0.08, MetaSVM -1.10, Uncertain significance, Cardiovascular phenotype
- E14V (p.Glu14Val), cosmic curated COSV10458, Ensembl rs1574423658
- p.Glu14 Glu15insGlyGluGluGluGlu, gnomAD 2-73385903-T-TGGA, CADD 21.40
- E14G (p.Glu14Gly), gnomAD 2-73385906-AGGAGG, CADD 30.00
- E14R (p.Glu14Arg), gnomAD 2-73385906-AG-A, CADD 27.00
- E15G (p.Glu15Gly), TOPMed rs1670508138
- p.Glu15 Glu28del, gnomAD 2-73385903-TGGAGG, CADD 21.00
- E15V (p.Glu15Val), gnomAD 2-73385912-A-T, MetaLR 0.08, MetaSVM -1.11
- p.Glu15 Glu16insAla, rs1558624515, gnomAD 2-73385912-A-AGGC, CADD 21.90
- E15E (p.Glu15Glu), rs1558624512, gnomAD 2-73385913-G-A, CADD 14.60
- E16* (p.Glu16Ter), rs1174023229, ClinGen CA347250477, ClinVar RCV003502112, TOPMed rs1174023229, AlphaMissense 0.21, MetaLR 0.04, Pathogenic
- E16K (p.Glu16Lys), rs1174023229, ClinGen CA347250478, ClinVar RCV001766036, ClinVar RCV002334681, AlphaMissense 0.21, MetaLR 0.04, Uncertain significance, Cardiovascular phenotype; not provided
- p.Glu16 Glu28del, gnomAD 2-73385904-GGAGGA, CADD 21.10
- E16G (p.Glu16Gly), rs1491137264, gnomAD 2-73385912-AGG-A, CADD 29.50
- E16R (p.Glu16Arg), rs1558624515, gnomAD 2-73385912-AG-A, CADD 29.00
- p.Glu16 Glu17insLys, gnomAD 2-73385914-G-GAGA, CADD 21.90
- E16V (p.Glu16Val), gnomAD 2-73385915-A-T, MetaLR 0.08, MetaSVM -1.11
- E16A (p.Glu16Ala), gnomAD 2-73385915-A-C, MetaLR 0.08, MetaSVM -1.11
- E16E (p.Glu16Glu), gnomAD 2-73385916-G-A, CADD 13.30
- E17* (p.Glu17Ter), TOPMed rs1407290993, gnomAD rs1407290993, CADD 36.00
- E17K (p.Glu17Lys), TOPMed rs1407290993, gnomAD rs1407290993, MetaLR 0.06, MetaSVM -1.08, Uncertain significance, Cardiovascular phenotype; not provided
- p.Glu17 Glu28del, gnomAD 2-73385907-GGAGGA, CADD 21.20
- E17R (p.Glu17Arg), gnomAD 2-73385915-AGGAG-, CADD 27.30
- E17G (p.Glu17Gly), rs2104057087, gnomAD 2-73385915-AGGAGG, CADD 27.30
- p.Glu17 Glu18insLys, gnomAD 2-73385917-G-GAGA, CADD 20.90
- E17V (p.Glu17Val), gnomAD 2-73385918-A-T, MetaLR 0.06, MetaSVM -1.09
- E17E (p.Glu17Glu), rs1553396127, gnomAD 2-73385919-G-A, CADD 11.40
- E18A (p.Glu18Ala), rs1159662032, ClinGen CA347250495, ClinVar RCV004521803, AlphaMissense 0.16, MetaLR 0.03, Uncertain significance, Cardiovascular phenotype
- E18V (p.Glu18Val), gnomAD rs1159662032, AlphaMissense 0.16, MetaLR 0.03
- E18K (p.Glu18Lys), Ensembl rs906421049
- p.Glu18 Glu28del, gnomAD 2-73385903-TGGAGG, CADD 21.20
- E18G (p.Glu18Gly), gnomAD 2-73385918-AGG-A, CADD 23.50
- E18* (p.Glu18Ter), gnomAD 2-73385920-G-T, CADD 32.00
- p.Glu18 Glu19insVal, gnomAD 2-73385921-A-AGGT, CADD 9.59
- E18D (p.Glu18Asp), gnomAD 2-73385922-G-C, MetaLR 0.03, MetaSVM -1.04
- E18E (p.Glu18Glu), rs1670509008, gnomAD 2-73385922-G-A, CADD 7.15
- E19K (p.Glu19Lys), rs939208094, ClinGen CA50368738, ClinVar RCV000669999, ClinVar RCV001662738, MetaLR 0.03, MetaSVM -1.01, Uncertain significance
- E19A (p.Glu19Ala), NCI-TCGA TCGA novel, MetaLR 0.02, MetaSVM -0.99, Uncertain significance, Cardiovascular phenotype
- p.Glu19 Glu28del, gnomAD 2-73385913-GGAGGA, CADD 21.20
- p.Glu19 Glu20insTer, rs1574423697, gnomAD 2-73385920-G-GAGG, CADD 21.90
- E19G (p.Glu19Gly), gnomAD 2-73385921-AGG-A, CADD 17.90
- E19V (p.Glu19Val), gnomAD 2-73385924-A-T, MetaLR 0.02, MetaSVM -0.99
- E19E (p.Glu19Glu), rs866503570, gnomAD 2-73385925-G-A, CADD 5.18
- E19D (p.Glu19Asp), gnomAD 2-73385925-G-T, MetaLR 0.02, MetaSVM -0.98
- E20V (p.Glu20Val), Ensembl rs1558624552, MetaLR 0.04, MetaSVM -1.06
- E20K (p.Glu20Lys), rs2465970198, ClinGen CA347250507, ClinVar RCV003017152, MetaLR 0.05, MetaSVM -1.07, Uncertain significance, Alstrom syndrome
- p.Glu20 Glu28del, rs55889738, gnomAD 2-73385903-TGGAGG, CADD 21.40
- E20R (p.Glu20Arg), gnomAD 2-73385924-AGGAG-, CADD 22.20
- E20G (p.Glu20Gly), rs767882166, gnomAD 2-73385924-AGG-A, CADD 21.60
- p.Glu20 Glu21insGln, rs1553396137, gnomAD 2-73385926-G-GAGC, CADD 11.40
- E20E (p.Glu20Glu), rs183407241, gnomAD 2-73385928-G-A, CADD 7.62
- E21* (p.Glu21Ter), rs1438410766, ClinGen CA347250516, ClinVar RCV001883877, TOPMed rs1438410766, CADD 34.00, Pathogenic
- E21K (p.Glu21Lys), TOPMed rs1438410766, gnomAD rs1438410766, Uncertain significance, Alstrom syndrome
- p.Glu21 Glu28del, rs55889738, gnomAD 2-73385903-TGGAGG, CADD 21.50
- E21G (p.Glu21Gly), gnomAD 2-73385927-AGG-A, CADD 23.10
- E21R (p.Glu21Arg), rs753006733, gnomAD 2-73385927-AG-A, CADD 21.70
- E21Q (p.Glu21Gln), gnomAD 2-73385929-G-C, MetaLR 0.03, MetaSVM -1.05
- p.Glu21 Glu22insLys, rs905301935, gnomAD 2-73385929-G-GAGA, CADD 14.50
- E21V (p.Glu21Val), gnomAD 2-73385930-A-T, MetaLR 0.03, MetaSVM -1.00
- E21A (p.Glu21Ala), gnomAD 2-73385930-A-C, MetaLR 0.02, MetaSVM -1.01
- E21E (p.Glu21Glu), rs1004961829, gnomAD 2-73385931-G-A, CADD 8.30
- E21D (p.Glu21Asp), gnomAD 2-73385931-G-T, MetaLR 0.03, MetaSVM -1.04
- E22K (p.Glu22Lys), Ensembl rs1574423734, MetaLR 0.03, MetaSVM -1.05
- p.Glu22 Glu28del, rs55889738, gnomAD 2-73385903-TGGAGG, CADD 21.60
- E22G (p.Glu22Gly), gnomAD 2-73385930-AGG-A, CADD 22.70
- E22R (p.Glu22Arg), gnomAD 2-73385930-AG-A, CADD 22.70
- p.Glu22 Glu23insLys, rs777844728, gnomAD 2-73385932-G-GAGA, CADD 10.30
- E22E (p.Glu22Glu), rs1574423753, gnomAD 2-73385934-G-A, CADD 3.93
- E23K (p.Glu23Lys), Ensembl rs1670510644
- E23A (p.Glu23Ala), rs2465970389, ClinGen CA347250536, ClinVar RCV003382190, Uncertain significance, Cardiovascular phenotype
- E23D (p.Glu23Asp), Ensembl rs1054040147, MetaLR 0.02, MetaSVM -0.98, Likely benign
- p.Glu23 Glu28del, rs55889738, gnomAD 2-73385903-TGGAGG, CADD 21.60
- p.Glu23 Glu24insLysGlu, rs1558624579, gnomAD 2-73385932-G-GAGG, CADD 10.20
- E23G (p.Glu23Gly), gnomAD 2-73385933-AGG-A, CADD 20.50
- E23R (p.Glu23Arg), gnomAD 2-73385933-AGGAG-, CADD 20.40
- E23* (p.Glu23Ter), gnomAD 2-73385935-G-T, CADD 33.00
- E23V (p.Glu23Val), gnomAD 2-73385936-A-T, MetaLR 0.02, MetaSVM -1.00
- E23E (p.Glu23Glu), rs1054040147, gnomAD 2-73385937-G-A, CADD 3.65
- p.Glu24 Glu28del, rs55889738, gnomAD 2-73385903-TGGAGG, CADD 21.70
- E24K (p.Glu24Lys), gnomAD 2-73385936-AGGAG-, CADD 19.10
- E24R (p.Glu24Arg), gnomAD 2-73385936-AGGAGG, CADD 19.90
- E24G (p.Glu24Gly), rs1491508985, gnomAD 2-73385936-AGG-A, CADD 16.60
- p.Glu24 Glu25insAspGlu, gnomAD 2-73385937-G-GGAG, CADD 6.33
- E24V (p.Glu24Val), gnomAD 2-73385939-A-T, MetaLR 0.02, MetaSVM -1.06
- E24A (p.Glu24Ala), gnomAD 2-73385939-A-C, MetaLR 0.01, MetaSVM -1.06
- E24D (p.Glu24Asp), gnomAD 2-73385940-G-T, MetaLR 0.02, MetaSVM -0.99
- E24E (p.Glu24Glu), rs1483677896, gnomAD 2-73385940-G-A, CADD 5.93
- E25* (p.Glu25Ter), rs1285425883, ClinGen CA347250547, ClinVar RCV001931192, Ensembl rs1285425883, CADD 32.00, Pathogenic
- E25K (p.Glu25Lys), Ensembl rs1285425883, MetaLR 0.04, MetaSVM -1.00, Pathogenic
- p.Glu25 Glu28del, rs55889738, gnomAD 2-73385903-TGGAGG, CADD 21.70
- E25R (p.Glu25Arg), rs1491515884, gnomAD 2-73385939-AGG-A, CADD 20.50
- E25A (p.Glu25Ala), gnomAD 2-73385942-A-C, MetaLR 0.04, MetaSVM -0.99
- E25D (p.Glu25Asp), gnomAD 2-73385943-A-C, MetaLR 0.03, MetaSVM -1.05
- E25E (p.Glu25Glu), rs13009043, gnomAD 2-73385943-A-G, CADD 6.93
- E26A (p.Glu26Ala), rs1670512146, ClinGen CA347250558, ClinVar RCV002715052, ClinVar RCV003167637, MetaLR 0.03, MetaSVM -0.98, Uncertain significance, Alstrom syndrome; Cardiovascular phenotype
- E26D (p.Glu26Asp), gnomAD rs13009604, MetaLR 0.03, MetaSVM -1.01, Likely benign
- E26Q (p.Glu26Gln), rs2465970539, ClinGen CA347250556, ClinVar RCV002633307, Uncertain significance, Alstrom syndrome
- p.Glu26 Glu28del, rs55889738, gnomAD 2-73385903-TGGAGG, CADD 21.80
- E26R (p.Glu26Arg), gnomAD 2-73385942-AAGAG-, CADD 19.30
- E26G (p.Glu26Gly), gnomAD 2-73385943-A-AGGA, CADD 14.20
- E26* (p.Glu26Ter), gnomAD 2-73385943-A-AT, CADD 15.30
- E26K (p.Glu26Lys), gnomAD 2-73385944-G-A, MetaLR 0.03, MetaSVM -0.99
- E26V (p.Glu26Val), gnomAD 2-73385945-A-T, MetaLR 0.04, MetaSVM -0.97
- E26E (p.Glu26Glu), rs13009604, gnomAD 2-73385946-G-A, CADD 6.45
- p.Glu26 Glu27insAsp, gnomAD 2-73385946-G-GGAC, CADD 10.10
- E27G (p.Glu27Gly), TOPMed rs1016245881, gnomAD rs1016245881, MetaLR 0.03, MetaSVM -1.02
- p.Glu27 Glu28del, rs55889738, gnomAD 2-73385903-TGGAGG, CADD 21.60
- E27R (p.Glu27Arg), rs1553396120, gnomAD 2-73385942-A-AGG, CADD 16.10
- E27K (p.Glu27Lys), gnomAD 2-73385947-G-A, MetaLR 0.03, MetaSVM -1.02
- E27A (p.Glu27Ala), gnomAD 2-73385947-G-GCTG, CADD 21.40
- E27D (p.Glu27Asp), gnomAD 2-73385949-G-T, MetaLR 0.03, MetaSVM -1.05
- p.Glu27 Glu28insAsp, gnomAD 2-73385949-G-GGAC, CADD 13.30
- E27E (p.Glu27Glu), rs1223853236, gnomAD 2-73385949-G-A, CADD 8.14
- E28A (p.Glu28Ala), Ensembl rs2104057924, MetaLR 0.03, MetaSVM -1.02
- E28K (p.Glu28Lys), rs1670512542, ClinGen CA347250570, ClinVar RCV001755146, ClinVar RCV002489790, MetaLR 0.02, MetaSVM -0.98, Uncertain significance, Alstrom syndrome; not provided; Cardiovascular phenotype
- p.Glu28dup, rs55889738, gnomAD 2-73385903-T-TGGA, CADD 21.80
- E28del (p.Glu28del), rs55889738, gnomAD 2-73385903-TGGA-T, CADD 21.50
- E28R (p.Glu28Arg), gnomAD 2-73385948-A-AGCG, CADD 22.70
- E28G (p.Glu28Gly), gnomAD 2-73385951-A-G, MetaLR 0.05, MetaSVM -1.00
Public ALMS1 analysis runs
- ALMS1 analysis run — ALMS1 (6,651 variants) — completed 2026-08-21